Enter assignee name

EPO Patents = 3

Forward Citations = 24

Loading Chart...

5 inventors (with patents filed for the assignee):

John Gerard Geisler (7 out of 7 patents)

Robert Alonso (7 out of 18 patents)

Narsimha Reddy Penthala (2 out of 16 patents)

4. Zaineb Albayati (2 out of 2 patents)

5. Peter Anthony Crooks (2 out of 97 patents)

7 patents: Sort by Forward Citations

1. 11717497 - Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases (2023-08-08),

2. 11406642 - DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases (2022-08-09),

3. 10864173 - Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases (2020-12-15),

4. 10548900 - DNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases (2020-02-04),

5. 10220006 - Induced expression of brain derived neurotrophic factor (BDNF) for treatment of Neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases (2019-03-05),

6. 9974755 - Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases (2018-05-22),

7. 9763896 - Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases (2017-09-19),

Mitochon Pharmaceuticals, Inc. is a biotechnology company focused on developing novel therapies for mitochondrial diseases. With a mission to improve the lives of patients suffering from mitochondrial dysfunction, Mitochon is at the forefront of research and innovation in this field. The company's pipeline includes promising drug candidates targeting various mitochondrial disorders, offering hope for those affected by these rare and debilitating conditions.

Profile summary based on public USPTO records.